Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients

被引：14

作者：

Peter, Joy ^{[1
]}

Nelson, David R. ^{[1
]}

机构：

[1] Univ Florida, Dept Med, Div Gastroenterol & Hepatol, Gainesville, FL USA

来源：

LIVER INTERNATIONAL | 2015年 / 35卷

关键词：

hepatitis C; treatment; direct acting antivirals; ACTING ANTIVIRAL AGENTS; HCV NS5A INHIBITOR; SOFOSBUVIR; GENOTYPE; DACLATASVIR; ABT-450/R-OMBITASVIR; LEDIPASVIR; RIBAVIRIN; DASABUVIR;

D O I：

10.1111/liv.12718

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Over the past year, interferon (IFN) free dosing regimens have become available to treat chronic hepatitis C. Offering high rates of sustained virological response (SVR), short treatment and improved tolerability, IFN-free treatment now represents the paradigm for both treatment-naive and -experienced patients. Patients with prior treatment failure, in particular those with cirrhosis, still represent some of the most difficult to treat, but the availability of multiple agents that can interrupt several steps of the HCV lifecycle affords providers and patients with options that can be combined and individually tailored to each patient's unique needs to obtain high rates of SVR.

引用

页码：65 / 70

页数：6

共 26 条

[1] Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].

Afdhal, Nezam ;

Zeuzem, Stefan ;

Kwo, Paul ;

Chojkier, Mario ;

Gitlin, Norman ;

Puoti, Massimo ;

Romero-Gomez, Manuel ;

Zarski, Jean-Pierre ;

Agarwal, Kosh ;

Buggisch, Peter ;

Foster, Graham R. ;

Braeu, Norbert ;

Buti, Maria ;

Jacobson, Ira M. ;

Subramanian, G. Mani ;

Ding, Xiao ;

Mo, Hongmei ;

Yang, Jenny C. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Mangia, Alessandra ;

Marcellin, Patrick .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898

[2] Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection [J].

Afdhal, Nezam ;

Reddy, K. Rajender ;

Nelson, David R. ;

Lawitz, Eric ;

Gordon, Stuart C. ;

Schiff, Eugene ;

Nahass, Ronald ;

Ghalib, Reem ;

Gitlin, Norman ;

Herring, Robert ;

Lalezari, Jacob ;

Younes, Ziad H. ;

Pockros, Paul J. ;

Di Bisceglie, Adrian M. ;

Arora, Sanjeev ;

Subramanian, G. Mani ;

Zhu, Yanni ;

Dvory-Sobol, Hadas ;

Yang, Jenny C. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Sulkowski, Mark ;

Kwo, Paul .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) :1483-1493

[3]

American Association for the Study of Liver Diseases/Infectious Diseases Society of America/International Antiviral Society (AASLD/IDSA/IAS)-USA, REC TEST MAN TREAT H

[4] ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection [J].

Andreone, Pietro ;

Colombo, Massimo G. ;

Enejosa, Jeffrey V. ;

Koksal, Iftihar ;

Ferenci, Peter ;

Maieron, Andreas ;

Muellhaupt, Beat ;

Horsmans, Yves ;

Weiland, Ola ;

Reesink, Henk W. ;

Rodrigues, Lino, Jr. ;

Hu, Yiran B. ;

Podsadecki, Thomas ;

Bernstein, Barry .

GASTROENTEROLOGY, 2014, 147 (02) :359-+

[5]

Bourliere M, 2014, HEPATOLOGY S, V60, P13

[6] ANTIVIRAL ACTIVITY AND RESISTANCE PROFILE OF THE NOVEL HCV NS5A INHIBITOR GS-5885 [J].

Cheng, G. ;

Peng, B. ;

Corsa, A. ;

Yu, M. ;

Nash, M. ;

Lee, Y. -J. ;

Xu, Y. ;

Kirschberg, T. ;

Tian, Y. ;

Taylor, J. ;

Link, J. O. ;

Delaney, W. .

JOURNAL OF HEPATOLOGY, 2012, 56 :S464-S464

[7]

Dvory-Sobol H, 2014, INT WORKSH ANT DRUG

[8] Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect [J].

Gao, Min ;

Nettles, Richard E. ;

Belema, Makonen ;

Snyder, Lawrence B. ;

Nguyen, Van N. ;

Fridell, Robert A. ;

Serrano-Wu, Michael H. ;

Langley, David R. ;

Sun, Jin-Hua ;

O'Boyle, Donald R. ;

Lemm, Julie A. ;

Wang, Chunfu ;

Knipe, Jay O. ;

Chien, Caly ;

Colonno, Richard J. ;

Grasela, Dennis M. ;

Meanwell, Nicholas A. ;

Hamann, Lawrence G. .

NATURE, 2010, 465 (7294) :96-U108

[9]

Harvoni&REG, 2014, FULL PRESCR INF

[10]

Hezode C, ANN M EASL LOND UK 9

← 1 2 3 →